Ginkgo Bioworks Holdings, Inc.

Equities

DNA

US37611X2099

Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2024-11-13 pm EST 5-day change 1st Jan Change
8.600 USD +2.50% Intraday chart for Ginkgo Bioworks Holdings, Inc. +3.49% -87.28%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Ginkgo Bioworks Holdings, Inc., Q3 2024 Earnings Call, Nov 12, 2024 Nov. 12
Earnings Flash (DNA) GINKGO BIOWORKS Reports Q3 Loss $-1.08 Nov. 12 MT
Earnings Flash (DNA) GINKGO BIOWORKS Posts Q3 Revenue $89M Nov. 12 MT
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 12 CI
Ginkgo Bioworks Holdings, Inc. Revises Revenue Guidance for the Year 2024 Nov. 12 CI
Ginkgo Bioworks Advances Collaboration with Merck Nov. 12 MT
Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing Nov. 12 CI
Lesaffre et Compagnie, SA acquired ALTAR from Ginkgo Bioworks Holdings, Inc.. Oct. 06 CI
Ginkgo Bioworks Launches Ginkgo Datapoints to Transform Ai Model Training in Biology Sep. 18 CI
Zymergen Settles SEC Charges Over Alleged Violations Linked to IPO Sep. 13 DJ
Ginkgo Bioworks Holdings, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-06-2024 11:30 AM Sep. 06
Earnings Flash (DNA) GINKGO BIOWORKS Posts Q2 Revenue $56M Aug. 08 MT
Ginkgo Bioworks Holdings, Inc., Q2 2024 Earnings Call, Aug 08, 2024 Aug. 08
Ginkgo Bioworks Holdings, Inc. Reaffirms Revenue Guidance for the Year 2024 Aug. 08 CI
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 Aug. 08 CI
Ginkgo Bioworks Partners With Syngenta Crop Protection for new Biologicals Jul. 16 MT
Goldman Sachs Adjusts Price Target on Ginkgo Bioworks to $0.30 From $0.80, Maintains Sell Rating Jul. 09 MT
Microba Life Sciences Completes Screening for Autoimmune Disease Program; Shares Down 3% Jun. 27 MT
Ginkgo Bioworks Holdings, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-30-2024 10:40 AM May. 30
Ginkgo Bioworks Holdings, Inc. Presents at TD. Cowen Virtual Sustainability & Energy Transition Summit, May-22-2024 03:25 PM May. 22
Ginkgo Bioworks Holdings Insider Bought Shares Worth $514,750, According to a Recent SEC Filing May. 16 MT
BTIG Downgrades Ginkgo Bioworks Holdings to Sell From Neutral, Price Target is $0.50 May. 15 MT
Morgan Stanley Trims Ginkgo Bioworks Price Target to $1 From $2, Maintains Equal Weight Rating May. 15 MT
Ginkgo Bioworks Holdings Insider Bought Shares Worth $271,815, According to a Recent SEC Filing May. 14 MT
Ginkgo Bioworks Holdings Insider Sold Shares Worth $1,606,162, According to a Recent SEC Filing May. 14 MT
Chart Ginkgo Bioworks Holdings, Inc.
DNA: Dynamic Chart
Logo Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Employees
1,218
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
surperformance-ratings-light-chart GINKGO-BIOWORKS-HOLDINGS-More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
6
Last Close Price
8.600USD
Average target price
8.800USD
Spread / Average Target
+2.33%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. DNA Stock
  4. News Ginkgo Bioworks Holdings, Inc.
  5. Ginkgo Bioworks, Visolis Partner to Improve Microbial Strain for Production of Bio-Isoprene, Sustainable Aviation Fuel